Primary head and neck cancer cell cultures are susceptible to proliferation of Epstein-Barr virus infected lymphocytes.
Epstein-barr virus
Head and neck cancer
Human papilloma virus
Lymphocyte
Primary cell culture model
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
13 Jan 2023
13 Jan 2023
Historique:
received:
01
04
2021
accepted:
23
12
2022
entrez:
13
1
2023
pubmed:
14
1
2023
medline:
18
1
2023
Statut:
epublish
Résumé
New concepts for a more effective anti-cancer therapy are urgently needed. Experimental flaws represent a major counter player of this development and lead to inaccurate and unreproducible data as well as unsuccessful translation of research approaches into clinics. In a previous study we have created epithelial cell cultures from head and neck squamous cell carcinoma (HNSCC) tissue. We characterize primary cell populations isolated from human papillomavirus positive HNSCC tissue for their marker expression by RT-qPCR, flow cytometry, and immunofluorescence staining. Their sensitivity to MDM2-inhibition was measured using cell viability assays. Primary HNSCC cell cultures showed the delayed formation of spheroids at higher passages. These spheroids mimicked the morphology and growth characteristics of other established HNSCC spheroid models. However, expression of epithelial and mesenchymal markers could not be detected in these cells despite the presence of the HNSCC stem cell marker aldehyde dehydrogenase 1 family member A1. Instead, strong expression of B- and T-lymphocytes markers was observed. Flow cytometry analysis revealed a heterogeneous mixture of CD3 + /CD25 + T-lymphocytes and CD19 + B-lymphocytes at a ratio of 4:1 at passage 5 and transformed lymphocytes at late passages (≥ passage 12) with CD45 + CD19 + CD20 + , of which around 10 to 20% were CD3 + CD25 + CD56 + . Interestingly, the whole population was FOXP3-positive indicative of regulatory B-cells (B In this study we present a primary cell culture of EBV-infected tumor-infiltrating B-lymphocytes, which could be used to study the role of these cells in tumor biology in future research projects. Moreover, by describing the detailed characteristics of these cells, we aim to caution other researchers in the HNSCC field to test for EBV-infected lymphocyte contaminations in primary cell cultures ahead of further experiments. Especially researchers who are interested in TIL-based adopted immunotherapy should exclude these cells in their primary tumor models, e.g. by MDM2-inhibitor treatment. BI-12-derived xenograft tumors represent a suitable model for in vivo targeting studies.
Sections du résumé
BACKGROUND
BACKGROUND
New concepts for a more effective anti-cancer therapy are urgently needed. Experimental flaws represent a major counter player of this development and lead to inaccurate and unreproducible data as well as unsuccessful translation of research approaches into clinics. In a previous study we have created epithelial cell cultures from head and neck squamous cell carcinoma (HNSCC) tissue.
METHODS
METHODS
We characterize primary cell populations isolated from human papillomavirus positive HNSCC tissue for their marker expression by RT-qPCR, flow cytometry, and immunofluorescence staining. Their sensitivity to MDM2-inhibition was measured using cell viability assays.
RESULTS
RESULTS
Primary HNSCC cell cultures showed the delayed formation of spheroids at higher passages. These spheroids mimicked the morphology and growth characteristics of other established HNSCC spheroid models. However, expression of epithelial and mesenchymal markers could not be detected in these cells despite the presence of the HNSCC stem cell marker aldehyde dehydrogenase 1 family member A1. Instead, strong expression of B- and T-lymphocytes markers was observed. Flow cytometry analysis revealed a heterogeneous mixture of CD3 + /CD25 + T-lymphocytes and CD19 + B-lymphocytes at a ratio of 4:1 at passage 5 and transformed lymphocytes at late passages (≥ passage 12) with CD45 + CD19 + CD20 + , of which around 10 to 20% were CD3 + CD25 + CD56 + . Interestingly, the whole population was FOXP3-positive indicative of regulatory B-cells (B
CONCLUSIONS
CONCLUSIONS
In this study we present a primary cell culture of EBV-infected tumor-infiltrating B-lymphocytes, which could be used to study the role of these cells in tumor biology in future research projects. Moreover, by describing the detailed characteristics of these cells, we aim to caution other researchers in the HNSCC field to test for EBV-infected lymphocyte contaminations in primary cell cultures ahead of further experiments. Especially researchers who are interested in TIL-based adopted immunotherapy should exclude these cells in their primary tumor models, e.g. by MDM2-inhibitor treatment. BI-12-derived xenograft tumors represent a suitable model for in vivo targeting studies.
Identifiants
pubmed: 36639629
doi: 10.1186/s12885-022-10481-y
pii: 10.1186/s12885-022-10481-y
pmc: PMC9840248
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Informations de copyright
© 2023. The Author(s).
Références
Cancers (Basel). 2018 Jun 22;10(7):
pubmed: 29932446
J Thorac Oncol. 2019 May;14(5):914-923
pubmed: 30735815
Mol Pathol. 1999 Feb;52(1):42-6
pubmed: 10439839
Blood Adv. 2022 Feb 8;6(3):891-901
pubmed: 34861697
Arch Surg. 1990 Feb;125(2):200-5
pubmed: 1689143
Proc Natl Acad Sci U S A. 1974 Sep;71(9):3565-9
pubmed: 4139718
Int J Clin Exp Med. 2010 Feb 22;3(1):69-83
pubmed: 20369042
Ann Oncol. 2018 Dec 1;29(12):2313-2327
pubmed: 30307465
J Neurooncol. 2016 Oct;130(1):19-29
pubmed: 27436101
EMBO Mol Med. 2017 Jul;9(7):918-932
pubmed: 28526679
Anticancer Res. 2019 Sep;39(9):4995-5001
pubmed: 31519606
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Clin Rev Allergy Immunol. 2017 Jun;52(3):364-372
pubmed: 27339600
Int J Cancer. 2017 Mar 15;140(6):1356-1363
pubmed: 27935045
Am J Clin Pathol. 2019 Oct 7;152(5):656-665
pubmed: 31305879
Blood. 1998 Aug 15;92(4):1374-83
pubmed: 9694726
J Immunol Methods. 1987 Aug 24;102(1):127-41
pubmed: 3305708
J Immunol. 2005 May 15;174(10):6477-89
pubmed: 15879151
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
J Thorac Oncol. 2015 Sep;10(9):1301-1310
pubmed: 26291010
Oncol Lett. 2015 Sep;10(3):1281-1286
pubmed: 26622664
Cancer J. 2017 Mar/Apr;23(2):138-143
pubmed: 28410302
Oncoimmunology. 2017 May 8;6(6):e1323617
pubmed: 28680763
Biochem Biophys Res Commun. 2009 Jul 31;385(3):307-13
pubmed: 19450560
Med Oncol. 2013 Dec;30(4):727
pubmed: 24026663
Cancer Lett. 1999 May 3;139(1):33-41
pubmed: 10408906
Cells. 2019 Jun 07;8(6):
pubmed: 31181618
J Oral Pathol Med. 2020 Feb;49(2):126-136
pubmed: 31660637
J Immunol. 2010 Nov 1;185(9):4977-82
pubmed: 20962266
J Pineal Res. 2018 Apr;64(3):
pubmed: 29247557
J Clin Oncol. 2006 May 10;24(14):2137-50
pubmed: 16682732
Anticancer Res. 2017 Aug;37(8):4165-4172
pubmed: 28739701
Front Microbiol. 2016 Oct 25;7:1602
pubmed: 27826287
Sci Rep. 2017 Dec 12;7(1):17359
pubmed: 29234119
Cancer Res. 1970 Sep;30(9):2434-7
pubmed: 4319907
Hum Pathol. 2018 Sep;79:18-41
pubmed: 29885408
Int J Cancer. 1989 Aug 15;44(2):219-24
pubmed: 2503456
Patholog Res Int. 2018 Apr 04;2018:4810751
pubmed: 29850009
Laryngoscope. 2017 Dec;127(12):2777-2783
pubmed: 28561270
Lung Cancer. 2012 Jan;75(1):45-57
pubmed: 21684623
Head Neck. 2010 Sep;32(9):1195-201
pubmed: 20073073
Clin Cancer Res. 2019 Mar 1;25(5):1486-1493
pubmed: 30518633
Cancer Sci. 2017 Mar;108(3):283-289
pubmed: 28064442
Oncoimmunology. 2015 May 22;4(6):e1002726
pubmed: 26155410
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Oncotarget. 2016 Mar 8;7(10):11018-32
pubmed: 26783961
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Anticancer Res. 2010 Sep;30(9):3473-8
pubmed: 20944125
Acta Oncol. 2019 Oct;58(10):1489-1494
pubmed: 31510843
Nat Biotechnol. 2019 Sep;37(9):969-971
pubmed: 31485043
Acta Oncol. 2018 Sep;57(9):1165-1172
pubmed: 29493423
Int J Cancer. 2004 Jul 10;110(5):701-9
pubmed: 15146560
Cancer Res. 2008 Jul 1;68(13):5405-13
pubmed: 18593943
Clin Cancer Res. 2008 Jul 1;14(13):4085-95
pubmed: 18593985
PLoS Genet. 2019 Apr 10;15(4):e1008039
pubmed: 30970016
Otolaryngol Head Neck Surg. 1986 Sep;95(2):142-52
pubmed: 2954014
J Pathol Transl Med. 2017 Jul;51(4):352-358
pubmed: 28592786